Search

Background: Patients with severe coronavirus disease 2019 (COVID-19) often rapidly deteriorate with severe dyspnea and should receive early specialist palliative care (SPC) as intensive symptom management may be required at the end of life. Currently, there is a paucity of data identifying triggers for early SPC involvement. Objective : To identify risk factors among nonventilated patients with severe COVID-19 who required high opioid and/or benzodiazepines (BZD) use for the control of dyspnea. Methods: This is a retrospective cohort study of nonventilated patients with COVID-19 admitted to the National Centre for Infectious Diseases in Singapore and seen by SPC between January 2021 and July 2022. We collected baseline demographics, comorbidities, 4C mortality score (International Severe Acute Respiratory Infection Consortium-Comprehensive Clinical Characterization Collaboration [ISARIC-4C]), and COVID-19 vaccination status. Clinical and laboratory results, dyspnea by numerical rating scale, and palliative-related treatments were recorded at the first SPC review, when symptoms peaked, and the last SPC review. Patients with morphine equivalent daily dose (MEDD) of ≥45mg and/or BZD use for dyspnea control were grouped as high users, while patients with MEDD <45mg and no BZD use were low users. Results: Among 234 patients, 119 (50.9%) were high users. Multivariate analysis showed that subjects with higher dyspnea (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.45-2.08) and lower ISARIC-4C scores (OR 0.77, 95% CI 0.67-0.88) at first SPC review were predictive of high users. High users also required higher supplemental oxygen and had higher inpatient mortality rates. Conclusions: High dyspnea score is predictive of high opioid and/or BZD use for symptom control in nonventilated patients with severe COVID-19. Such patients with high mortality rates should be seen early by SPC.

Introduction: Cancer is a pervasive global problem with significant healthcare utilisation and cost. Emergency departments (EDs) see large numbers of patients with oncologic emergencies and act as "gate-keepers" to subsequent hospital admissions. A proportion of such hospital admissions are rapidly discharged within 2 days and may be potentially avoidable., Methods: Over a 6-month period, we conducted a retrospective audit of active cancer patients presenting to the ED with subsequent admission to the Department of Medical Oncology. Our aims were to identify independent factors associated with a length of stay ≤2 days; and characterise the clinical and resource needs of these short admissions., Results: Among all medical oncology admissions, 24.4% were discharged within 2 days. Compared to longer stayers, patients with short admissions were significantly younger ( P =0.010), had lower National Early Warning Scores (NEWS) ( P =0.006), and had a lower proportion of gastrointestinal and hepatobiliary cancers ( P =0.005). Among short admissions, common presenting medical problems were infections (n=144, 36.3%), pain (n=116, 29.2%), gastrointestinal complaints (n=85, 21.4%) and respiratory complaints (n=76, 19.1%). These admissions required investigations and treatments already available at the ED., Conclusion: Short admissions have low resource needs and may be managed in the ED. This may help save valuable inpatient bed-days and reduce overall healthcare costs.